Completed PHASE3 INTERVENTIONAL 2-arm NCT00471146

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.

Sponsor: Pfizer

Conditions Carcinoma, Pancreatic Ductal

Interventions AG-013736 Gemcitabine placebo

Updated 7 times since 2017 Last updated: Jun 14, 2012 Started: Jul 31, 2007 Primary completion: Jan 31, 2009 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00471146, this PHASE3 trial focuses on Carcinoma, Pancreatic Ductal and remains completed. Sponsored by Pfizer, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Alton, United States , Amsterdam, Netherlands , Andhra, India , Annapolis, United States , Antioch, United States , Atlanta, United States , Augusta, United States , Austin, United States , Bahía Blanca, Argentina and 152 more locations